Compare Incyte Corporation (INCY) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Ferrari NV — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Ferrari NV trades at $389.91 (market cap $67.35B). The key difference: Ferrari NV is far larger — about 2.9× Incyte Corporation's market cap, and Ferrari NV pays a 1.09% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Ferrari NV for 126 Days on average.
| INCY | RACE | |
|---|---|---|
Market Cap | $22.85B | $67.35B |
Volume | 1,927,029 | 390,618 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $436.54 |
52-Week Low | $83.80 | $314.63 |
Typical Hold Time | 33 Days | 126 Days |
Enterprise Value | $18.35B | $69.22B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
Ferrari (RACE) trades at $388.28, up 0.49% today, with a bearish technical signal but strong fundamentals. The stock shows consistent revenue growth, reaching $7.15B in 2025, and robust profitability with a 22.25% net income margin. Recent quarterly earnings have exceeded expectations, and the company is executing a share buyback program. Technical indicators point to near-term pressure, with support at $381 and resistance at $390.
The outlook remains positive due to strong brand equity and financial performance, with a consensus price target of $462.75 implying 19% upside. Risks include high valuation multiples and exposure to economic cycles. Wall Street sentiment is bullish, with 74% of analysts rating it a Buy, supported by institutional accumulation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
